Prasugrel

證據等級: L5

預測適應症: 10 個

Prasugrel: From Antiplatelet Therapy to Pulmonary Hypertension

One-Sentence Summary

Prasugrel is a thienopyridine-class, irreversible P2Y12 receptor antagonist used as antiplatelet therapy (evidence in this pack references its established role alongside clopidogrel following PCI in acute coronary syndrome). The TxGNN model predicts it may be effective for Pulmonary Hypertension, but currently only 2 clinical trials and 2 publications are linked to this prediction, and neither directly studies prasugrel in pulmonary hypertension.

Quick Overview

Item	Content
Original Indication	Not recorded in Taiwan regulatory data (drug is not marketed in Taiwan; no NDA/license records). Globally, prasugrel is a P2Y12 inhibitor used for antiplatelet therapy after PCI in ACS (referenced indirectly via literature PMID 21241206)
Predicted New Indication	Pulmonary Hypertension
TxGNN Prediction Score	99.88%
Evidence Level	L5
Taiwan Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on information available in this evidence pack, prasugrel is an irreversible P2Y12 receptor antagonist (thienopyridine-class antiplatelet drug), the same pharmacological class as clopidogrel.

The mechanistic link to pulmonary hypertension is weak and subtype-specific at best. Only the chronic thromboembolic pulmonary hypertension (CTEPH) subtype involves thrombotic pathology, where antiplatelet/anticoagulant mechanisms could theoretically play a role. However, idiopathic and most other pulmonary hypertension subtypes are driven primarily by pulmonary vascular remodeling rather than platelet-mediated thrombosis, so P2Y12 inhibition does not have a clear, disease-modifying rationale for the broader pulmonary hypertension category.

Consistent with this, the retrieved clinical trials and literature do not actually study prasugrel in pulmonary hypertension patients — they were flagged by the evaluators as Grade C relevance (background co-occurrence in antithrombotic/anticoagulant research areas only). This supports classifying the evidence level as L5 (model prediction only, no direct supporting studies).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04846556	N/A	Completed	300	Retrospective study on cancer-associated venous thromboembolism, evaluating eligibility for the CARAVAGGIO trial. Does not involve prasugrel or pulmonary hypertension; relevance graded C (background anticoagulation population overlap only).
NCT03993119	N/A	Completed	500	Observational, cross-sectional description of NOAC management in elderly non-valvular atrial fibrillation patients in Spain. Not prasugrel-specific and not a pulmonary hypertension study; relevance graded C.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21241206	2011	Cohort	Curr Med Res Opin	Evaluates factors affecting clopidogrel/prasugrel adherence after PCI in ACS patients; establishes prasugrel’s established antiplatelet indication context but does not address pulmonary hypertension.
34713782	2021	Cohort	Kardiologiia	ACTIV SARS-CoV-2 registry analysis of background chronic-disease therapy on COVID-19 outcomes; not specific to prasugrel or pulmonary hypertension.

Taiwan Market Information

Currently not marketed in Taiwan — no NDA or license records are available (total_licenses = 0).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are currently unavailable in this evidence pack — TFDA label warnings/contraindications retrieval is flagged as a Blocking data gap that must be resolved before any safety screening.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L5 — the pulmonary hypertension prediction is currently supported only by TxGNN’s model score, with no clinical trials or literature directly studying prasugrel in this indication. The mechanistic rationale is also non-specific, applying at best to a single pulmonary hypertension subtype (CTEPH) rather than the disease category as a whole.

To proceed, the following is needed:

TFDA package insert warnings/contraindications (DG001, Blocking — required before any S1 safety evaluation)
Detailed mechanism of action data from DrugBank (DG002, High severity)
Confirmation of prasugrel’s original approved indication and any future Taiwan license/market status
Targeted preclinical or clinical studies of prasugrel specifically in CTEPH or other pulmonary hypertension populations, since current evidence is indirect and non-specific
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.